KalVista Pharmaceuticals Inc (KALV)
NGM · Healthcare · Biotechnology
$27.00
+0.00%
Closing price as of 2026-06-12 · Source: TEK2day Finance
Key Metrics
Market Cap
$1.44B
Shares Outstanding
53.2M
P/S (TTM)
26.3x
Exchange
NGM
Currency
USD
About KalVista Pharmaceuticals Inc
KalVista Pharmaceuticals, Inc., a biopharmaceutical company, develops oral therapies for individuals for rare diseases with unmet needs. Its lead product candidate is EKTERLY, a fast-acting potent inhibitor of plasma kallikrein for the treatment of acute attacks of hereditary angioedema (HAE). The company is also developing is developing an orally disintegrating tablet formulation; KONFIDENT-KID for pediatric use with HAE; KONFIDENT; and KONFIDENT-S to evaluate sebetralstat and ODT formulation in adolescent and adult patients. KalVista Pharmaceuticals, Inc. is headquartered in Framingham, Massachusetts.
Quarterly Financials
| Metric | 2025-01-31 | 2025-04-30 | 2025-09-30 | 2026-03-31 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 13.7M | 40.9M |
| Gross Profit | 12.5M | 37.8M | ||
| Operating Income | (42.9M) | (50.0M) | (46.0M) | (23.4M) |
| Net Income | (48.5M) | (52.2M) | (49.5M) | (23.5M) |
| Diluted EPS | $-0.92 | N/A | $-0.92 | $-0.43 |
Annual Financials
| Metric | 2022-04-30 | 2023-04-30 | 2024-04-30 | 2025-04-30 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | (81.3M) | (95.1M) | (132.0M) | (183.0M) |
| Net Income | (82.3M) | (92.9M) | (126.6M) | (183.4M) |
| Diluted EPS | $-3.36 | $-3.33 | $-3.44 | $-3.69 |